Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece.
Semin Arthritis Rheum. 2011 Oct;41(2):170-7. doi: 10.1016/j.semarthrit.2011.01.006. Epub 2011 Mar 24.
Dickkopf-1 (DKK-1), an inhibitor of the Wnt pathway, has recently emerged as an important player in several critical aspects of bone biology.
We performed an extensive internet search (MEDLINE) using the key words Dickkopf-1 and the abbreviation DKK-1.
DKK-1 is a regulator of bone mass with increased expression linked to osteopenia and decreased expression to high bone mass. Moreover, it appears to actively participate in joint remodeling in animal models of arthritis, with increased levels related to bone resorption and decreased levels to new bone formation. Recent studies indicate its possible involvement in the remodeling process of human systemic rheumatic diseases such as rheumatoid arthritis and ankylosing spondylitis. DKK-1 may also play a role in osteoarthritis, metabolic bone disease (osteoporosis and Paget's disease), as well as multiple myeloma-associated bone disease and prostate cancer bone metastases.
DKK-1 is a regulator of bone mass and joint remodeling. It may be a promising therapeutic target in osteoporosis; monoclonal antibody-based inhibition of Dkk-1 is already under development for osteoporosis treatment. Its role as a regulator of joint remodeling in animal models requires further exploration in humans.
Dickkopf-1（DKK-1）是 Wnt 通路的抑制剂，最近在骨骼生物学的几个关键方面成为一个重要的角色。
我们使用关键词 Dickkopf-1 和缩写 DKK-1 进行了广泛的互联网搜索（MEDLINE）。
DKK-1 是骨量的调节剂，其表达增加与骨质疏松症有关，表达减少与高骨量有关。此外，它似乎在关节炎的动物模型中积极参与关节重塑，其水平升高与骨吸收有关，水平降低与新骨形成有关。最近的研究表明，它可能参与了人类风湿性疾病（如类风湿关节炎和强直性脊柱炎）的重塑过程。DKK-1 也可能在骨关节炎、代谢性骨病（骨质疏松症和 Pagets 病）以及多发性骨髓瘤相关骨病和前列腺癌骨转移中发挥作用。
DKK-1 是骨量和关节重塑的调节剂。它可能是骨质疏松症的一个有前途的治疗靶点；基于单克隆抗体的 Dkk-1 抑制已经在开发中用于骨质疏松症的治疗。它作为动物模型中关节重塑的调节剂的作用需要在人类中进一步探索。
